QQ客服 官方微博 反馈留言

	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
	Fang, Wenfeng; Yang, Yunpeng; Ma, Yuxiang; Hong, Shaodong; Lin, Lizhu; He, Xiaohui; Xiong, Jianping; Li, Ping; Zhao, Hongyun; Huang, Yan
刊名	LANCET ONCOLOGY
	2018
卷号	Vol.19 No.10页码:1338-1350
ISSN号	1470-2045
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1834416
专题	四川大学
作者单位	1.Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China 2.Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China 3.Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China,Dept Med Oncol, Collaborat Innovat Ctr Canc Med,Guangdong Key Lab, Guangzhou, Guangdong, Peoples R China 4.Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China,Dept Clin Res, Collaborat Innovat Ctr Canc Med,Guangdong Key Lab, Guangzhou, Guangdong, Peoples R China 5.Jiangsu Hengrui Med Co Ltd, Lianyungang, Peoples R China 6.Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China 7.Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
推荐引用方式 GB/T 7714	Fang, Wenfeng,Yang, Yunpeng,Ma, Yuxiang,et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. LANCET ONCOLOGY,2018,Vol.19 No.10:1338-1350.
APA	Fang, Wenfeng.,Yang, Yunpeng.,Ma, Yuxiang.,Hong, Shaodong.,Lin, Lizhu.,...&Huang, Yan.(2018).Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.LANCET ONCOLOGY,Vol.19 No.10,1338-1350.
MLA	Fang, Wenfeng,et al."Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials".LANCET ONCOLOGY Vol.19 No.10(2018):1338-1350.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。